Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-26T09:18:33.541Z Has data issue: false hasContentIssue false
  • English
  • Français

Prolonged use of dexmedetomidine in the paediatric cardiothoracic intensive care unit

Published online by Cambridge University Press:  20 January 2009

Sharon Bejian ,
Cassie Valasek ,
John J. Nigro ,
David C. Cleveland  and
Brigham C. Willis
Sharon Bejian
Affiliation:
Eller Congenital Heart Center, St. Joseph’s Hospital and Medical Center, Phoenix, Arizona
Cassie Valasek
Affiliation:
Eller Congenital Heart Center, St. Joseph’s Hospital and Medical Center, Phoenix, Arizona
John J. Nigro
Affiliation:
Eller Congenital Heart Center, St. Joseph’s Hospital and Medical Center, Phoenix, Arizona
David C. Cleveland
Affiliation:
Eller Congenital Heart Center, St. Joseph’s Hospital and Medical Center, Phoenix, Arizona
Brigham C. Willis*
Affiliation:
Eller Congenital Heart Center, St. Joseph’s Hospital and Medical Center, Phoenix, Arizona Department of Pediatrics, University of Arizona, Tucson, Arizona, United States of America
*
Correspondence to: Brigham C. Willis, M.D. Clinical Associate Professor of Pediatrics, University of Arizona, Eller Congenital Heart Center, St. Joseph’s Hospital and Medical Center, 500 W. Thomas Rd., Suite 500, Phoenix, AZ 85013, United States of America. Tel: (602) 406-2670; Fax: (602) 294-5273; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Dexmedetomidine is an α2-adrenergic agonist that causes sleep-like sedation and mild analgesia without narcosis or respiratory depression, and has relative cardiovascular stability. Due to these properties, it may be an effective agent for prolonged use in the sedation of patients in the paediatric cardiothoracic intensive care unit. We reviewed our experience with the drug to detail its safety and efficacy.

Methods

We conducted a retrospective chart review of all patients who received dexmedetomidine over a six month period in a dedicated paediatric cardiothoracic intensive care unit. Patients were identified from pharmacy records showing administration of drugs. We collected demographic data, information relating to doses of dexmedetomidine, physiologic parameters, and clinical outcomes.

Results

We identified 54 patients who received the drug. The median age of recipients was 6 months, with a range from 1 day to 16 years. The mean duration of administration was 37.3 hours, with a range from 2 to 177 hours. The mean duration of continuation of administration after extubation was 16.7 hours, with a range from zero to 112.5 hours. Physiologically, there were no clinically significant changes in mean arterial pressure, heart rate, respiratory rate, or saturations of oxygen before, during, or after utilization of the drug. Use of dexmedetomidine significantly reduced the need to administrate narcotics, and scores using the COMFORT system were not different between patients who received dexmedetomidine and those who did not.

Conclusions

In this limited and retrospective review, dexmedetomidine was found to be safe and efficacious. Its use as a sedative agent for extended periods of time in critically-ill children deserves investigation in a prospective and controlled manner.

Keywords

Sedationcardiac surgerycritical care
Type
Original Article
Information
Cardiology in the Young , Volume 19 , Issue 1 , February 2009 , pp. 98 - 104
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Tobias, JD. Dexmedetomidine: applications in pediatric critical care and pediatric anesthesiology. Pediatr Crit Care Med 2007; 8: 115–131.CrossRefGoogle ScholarPubMed
2. Shehabi, Y, Ruettimann, U, Adamson, H, Innes, R, Ickeringill, M. Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects. Intensive Care Med 2004; 30: 2188–2196.CrossRefGoogle ScholarPubMed
3. Walker, J, Maccallum, M, Fischer, C, Kopcha, R, Saylors, R, McCall, J. Sedation using dexmedetomidine in pediatric burn patients. J Burn Care Res 2006; 27: 206–210.Google Scholar
4. Venn, M, Newman, J, Grounds, M. A phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit. Intensive Care Med 2003; 29: 201–207.Google Scholar
5. Venn, RM, Grounds, RM. Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: patient and clinician perceptions. Br J Anaesth 2001; 87: 684–690.CrossRefGoogle ScholarPubMed
6. Venn, RM, Bryant, A, Hall, GM, Grounds, RM. Effects of dexmedetomidine on adrenocortical function, and the cardiovascular, endocrine and inflammatory responses in post-operative patients needing sedation in the intensive care unit. Br J Anaesth 2001; 86: 650–656.CrossRefGoogle ScholarPubMed
7. Buck, ML, Willson, DF. Use of dexmedetomidine in the pediatric intensive care unit. Pharmacotherapy 2008; 28: 1–57.Google Scholar
8. Chrysostomou, C, Di Filippo, S, Manrique, AM, et al. Use of dexmedetomidine in children after cardiac and thoracic surgery. Pediatr Crit Care Med 2006; 7: 126–131.Google Scholar
9. Phan, H, Nahata, MC. Clinical uses of dexmedetomidine in pediatric patients. Paediatr Drugs 2008; 10: 49–69.Google Scholar
10. Tobias, JD, Berkenbosch, JW. Sedation during mechanical ventilation in infants and children: dexmedetomidine versus midazolam. South Med J 2004; 97: 451–455.Google Scholar
11. Petroz, GC, Sikich, N, James, M, et al. A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children. Anesthesiology 2006; 105: 1098–1110.CrossRefGoogle ScholarPubMed
12. Ista, E, van Dijk, M, Tibboel, D, de Hoog, M. Assessment of sedation levels in pediatric intensive care patients can be improved by using the COMFORT “behavior” scale. Pediatr Crit Care Med 2005; 6: 58–63.Google Scholar
13. Doze, VA, Chen, BX, Maze, M. Dexmedetomidine produces a hypnotic-anesthetic action in rats via activation of central alpha-2 adrenoceptors. Anesthesiology 1989; 71: 75–79.Google Scholar
14. Nelson, LE, Lu, J, Guo, T, Saper, CB, Franks, NP, Maze, M. The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology 2003; 98: 428–436.Google Scholar
15. Rosen, DA, Daume, JT. Short duration large dose dexmedetomidine in a pediatric patient during procedural sedation. Anesth Analg 2006; 103: 68–69, table of contents.Google Scholar
16. Willigers, HM, Prinzen, FW, Roekaerts, PM, de Lange, S, Durieux, ME. Dexmedetomidine decreases perioperative myocardial lactate release in dogs. Anesth Analg 2003; 96: 657–664, table of contents.Google Scholar
17. Kamibayashi, T, Hayashi, Y, Mammoto, T, Yamatodani, A, Sumikawa, K, Yoshiya, I. Role of the vagus nerve in the antidysrhythmic effect of dexmedetomidine on halothane/epinephrine dysrhythmias in dogs. Anesthesiology 1995; 83: 992–999.Google Scholar
18. Roekaerts, PM, Prinzen, FW, De Lange, S. Beneficial effects of dexmedetomidine on ischaemic myocardium of anaesthetized dogs. Br J Anaesth 1996; 77: 427–429.Google Scholar
19. Hoffman, WE, Kochs, E, Werner, C, Thomas, C, Albrecht, RF. Dexmedetomidine improves neurologic outcome from incomplete ischemia in the rat. Reversal by the alpha 2-adrenergic antagonist atipamezole. Anesthesiology 1991; 75: 328–332.Google Scholar
20. Kuhmonen, J, Pokorny, J, Miettinen, R, et al. Neuroprotective effects of dexmedetomidine in the gerbil hippocampus after transient global ischemia. Anesthesiology 1997; 87: 371–377.CrossRefGoogle ScholarPubMed
21. Furst, SR, Weinger, MB. Dexmedetomidine, a selective alpha 2-agonist, does not potentiate the cardiorespiratory depression of alfentanil in the rat. Anesthesiology 1990; 72: 882–888.CrossRefGoogle Scholar
22. Taniguchi, T, Kidani, Y, Kanakura, H, Takemoto, Y, Yamamoto, K. Effects of dexmedetomidine on mortality rate and inflammatory responses to endotoxin-induced shock in rats. Crit Care Med 2004; 32: 1322–1326.CrossRefGoogle ScholarPubMed
23. Talke, P, Tong, C, Lee, HW, Caldwell, J, Eisenach, JC, Richardson, CA. Effect of dexmedetomidine on lumbar cerebrospinal fluid pressure in humans. Anesth Analg 1997; 85: 358–364.Google ScholarPubMed
24. Miyazaki, Y, Adachi, T, Kurata, J, Utsumi, J, Shichino, T, Segawa, H. Dexmedetomidine reduces seizure threshold during enflurane anaesthesia in cats. Br J Anaesth 1999; 82: 935–937.Google Scholar
25. Mirski, MA, Rossell, LA, McPherson, RW, Traystman, RJ. Dexmedetomidine decreases seizure threshold in a rat model of experimental generalized epilepsy. Anesthesiology 1994; 81: 1422–1428.Google Scholar
26. Maze, M, Virtanen, R, Daunt, D, Banks, SJ, Stover, EP, Feldman, D. Effects of dexmedetomidine, a novel imidazole sedative-anesthetic agent, on adrenal steroidogenesis: in vivo and in vitro studies. Anesth Analg 1991; 73: 204–208.Google Scholar
27. Asai, T, Mapleson, WW, Power, I. Differential effects of clonidine and dexmedetomidine on gastric emptying and gastrointestinal transit in the rat. Br J Anaesth 1997; 78: 301–307.CrossRefGoogle ScholarPubMed
28. Bloor, BC, Ward, DS, Belleville, JP, Maze, M. Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes. Anesthesiology 1992; 77: 1134–1142.CrossRefGoogle ScholarPubMed